Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

News Details

May 10, 2017

Dohmen's high-touch patient support model featured in PharmaVOICE

A recent issue of PharmaVOICE highlights how the integrated model for rare disease patient support helps improve therapy adherence and build better patient relationships.

The article, "How Well Do You Really Know Your Patients?” discusses how many orphan drug manufacturers are recognizing that the traditional model for commercialization and drug delivery doesn’t serve small patient populations well. Patient adherence suffers as therapies typically flow through a half-dozen disjointed, uncoordinated middlemen, including wholesalers, distributors, HUBs, specialty pharmacies and healthcare providers, before they make it to a patient.  

A unique wrap-around patient service model focuses on coordinated care, patient education and comprehensive support delivered by a single rare disease-focused business partner.

“By developing a personal relationship with our clients’ patients and empathizing with unique challenges and concerns, we can target interventions and support resources to ensure ongoing adherence and ultimately, help create a better quality of life,” shares Linda Newberry-Ferguson, Senior VP of Clinical Navigation,  Dohmen Life Science Services.

Download a copy of the article here.